Efficacy and safety of argatroban combined with plasmin in the treatment of acute cerebral infarction

Abstract

Objective To observe the effects of combined application of argatroban and plasmin on the degree of neurological function deficit and neutrophil (NEUT) count in patients with acute cerebral infarction (ACI) and their safety. Methods A total of 221 patients with ACI admitted to The First Affiliated Hospital of Dalian Medical University from October 2018 to January 2022 were selected as the research objects, and they were randomly divided into four groups: control group (n=71), plasmin group (n=42), argatroban group (n=40), and combined group (n=68). All four groups were given conventional treatment, and no other treatment was added to the control group. The plasmin group was added with plasmin injection by intravenous drip, 100 IU on the first day of treatment, and 300 IU on the second day. The argatroban group was pumped intravenously with 10 mg of argatroban injection every 12 hours. The combined group was given argatroban injection and plasmin injection every day (the usage was the same as before). The changes of neurological function deficit and blood NEUT count before and after treatment and the adverse reactions during treatment were observed and recorded. Results After treatment, except for the control group, the National Institutes of Health Stroke Scale (NIHSS) scores of the other three groups were significantly lower than those before treatment (P＜0.01). The NIHSS score of the combined group was significantly lower than that of the control group, the plasmin group and the argatroban group, with the statistically significant differences (P＜0.05). After treatment, except for the control group, the blood NEUT count of the other three groups decreased compared to before treatment(P＜0.05). Blood NEUT count in the combined group was significantly lower than that in the control group, plasmin group, and argatroban group, with the statistically significant differences (P＜0.05). There was no obvious adverse reactions in the four groups. Conclusion The combination of argatroban and plasmin in the treatment of ACI can significantly reduce blood NEUT count, effectively improve neurological function deficit, with significant short-term efficacy and good safety.

Keywords

• acute cerebral infarction， argatroban， plasmin， neurological function deficit， neutrophil count